Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study.
The objective of this study was to examine the effects of adjunctive treatment with the acetylcholinesterase inhibitor, donepezil, on cognitive deficits and psychopathology in schizophrenic patients treated with the antipsychotic, ziprasidone. The design of the study was double blind, placebo controlled, and longitudinal. Patients were treated with ziprasidone for 8 weeks, thereafter randomized to 4 months of double-blind adjunctive treatment with either donepezil (dose, 5-10 mg) or placebo. The severity of psychopathology (PANSS) and the cognitive deficits were examined at baseline and after 4 months. A total of 21 schizophrenic patients were enrolled, of whom 11 patients completed the trial (donepezil, n = 7; placebo, n = 4). There were no within- or between-group differences in changes on the Positive and Negative Syndrome Scale scores or a global cognitive score. Within-group improvements (all at trend level P = 0.07) were seen in the placebo group on Trail-Making Test B, immediate verbal recall, and set-shifting errors. The donepezil group showed a significant deterioration on planning efficiency (P = 0.04). Between-group differences were found between the lack of improvement in immediate verbal recall in the donepezil group and the improvement in the placebo group (P = 0.02), and between the deterioration of planning efficiency in the donepezil group and the stability in the placebo group (trend level, P = 0.07). Linear regression analyses showed that neither baseline psychopathology scores, baseline levels of cognitive deficits, nor psychopathology changes over time accounted for these changes in cognitive scores. The study found no evidence of improved cognition after treatment with donepezil, although the conclusions that can be drawn are limited by the small sample size.
Fagerlund
Birgitte
B
Department of Psychiatry E, Center for Neuropsychiatric Schizophrenia Research, Bispebjerg University Hospital, Copenhagen, Denmark. bfagerlund@email.com
Søholm
Bettina
B
Fink-Jensen
Anders
A
Lublin
Henrik
H
Glenthøj
Birte Y
BY
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D000077265:Donepezil; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007189:Indans / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects; D012559:Schizophrenia / Q000150:complications*; D013844:Thiazoles / Q000008:administration & dosage*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D002800:Cholinesterase Inhibitors; D007189:Indans; D010879:Piperazines; D010880:Piperidines; D013844:Thiazoles; C092292:ziprasidone; D000077265:Donepezil